"Apollonia" University of Iasi, Pacurari Street, No. 11, 700511, Iasi, Romania.
"Apollonia" University of Iasi, Pacurari Street, No. 11, 700511, Iasi, Romania.
Int J Biol Macromol. 2024 Apr;265(Pt 2):131027. doi: 10.1016/j.ijbiomac.2024.131027. Epub 2024 Mar 20.
Lung infections, such as: pneumonia, chronic obstructive cystic fibrosis, tuberculosis are generally caused by viruses, bacteria and fungi. As these infections are very difficult to treat, new therapeutic approaches are investigated in order to maximize the efficiency of the treatment and to reduce the major complications that can occur. The main objective of this study was focused on the preparation of drug-loaded peptides-functionalized microcapsules, obtained by a double emulsion, based on carboxylated chitosan (CMCS), poly(vinyl alcohol) (PVA) and an activator [4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride] (DMT-MM), for the dual active targeting and treatment of pulmonary infections. The microcapsules were functionalized on the surface with both CGSPGWVRC and indolicidin (IN) peptides, as effective ligands for the active targeting of both alveolar capillary endothelial cells and bacterial cells. FTIR spectroscopy confirmed the formation of ester and amide bonds into the structure of prepared microcapsules. Microcapsules diameter varied between 893 and 965 nm. The swelling degree in PBS, at pH 7.4, ranged between 1760 %- 2100 %. All the analyzed samples showed hemolysis degrees lower than 2 %, which demonstrated their non-hemolytic character. Evaluation of the impact of microcapsules on WI-38 normal human lung cells and RAW 264.7 mouse macrophages revealed a non-toxic or slightly cytotoxic effect. Internalization assay proved that microcapsules were localized at intracellular level.
肺部感染,如肺炎、慢性阻塞性囊性纤维化、肺结核,通常由病毒、细菌和真菌引起。由于这些感染很难治疗,因此正在研究新的治疗方法,以最大限度地提高治疗效率,并减少可能发生的主要并发症。本研究的主要目的是专注于制备载药肽功能化微胶囊,该微胶囊通过双重乳液法,以羧甲基壳聚糖(CMCS)、聚乙烯醇(PVA)和活化剂[4-(4,6-二甲氧基-1,3,5-三嗪-2-基)-4-甲基吗啉𬭩氯化物](DMT-MM)为基础,用于肺部感染的双重主动靶向和治疗。微胶囊表面用 CGSPGWVRC 和抑菌肽(IN)进行功能化,作为肺泡毛细血管内皮细胞和细菌细胞主动靶向的有效配体。傅里叶变换红外光谱(FTIR)证实了酯键和酰胺键的形成进入了制备的微胶囊结构中。微胶囊的直径在 893nm 到 965nm 之间变化。在 pH 值为 7.4 的 PBS 中的溶胀度在 1760%-2100%之间。所有分析的样品的溶血度均低于 2%,表明它们没有溶血特性。评估微胶囊对 WI-38 正常人类肺细胞和 RAW 264.7 小鼠巨噬细胞的影响表明,微胶囊具有非毒性或轻微细胞毒性作用。内化试验证明微胶囊定位于细胞内水平。